Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, open label study evaluating the pharmacokinetics of TX-001HR (1 mg E2/100 mg P4 or 0.5 mg E2/100 mg P4) in healthy post menopausal women

Trial Profile

A phase I, open label study evaluating the pharmacokinetics of TX-001HR (1 mg E2/100 mg P4 or 0.5 mg E2/100 mg P4) in healthy post menopausal women

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol/progesterone (Primary)
  • Indications Vasomotor symptoms
  • Focus Pharmacokinetics
  • Most Recent Events

    • 06 Oct 2018 Results assessing the Bioavailability of Estradiol and Progesterone for Moderate-to-Severe Vasomotor Symptom treatment with TX-001HR in REPLENISH and a Phase 1 trial, presented at the North American Menopause Society 2018 Annual Meeting
    • 26 Apr 2018 New trial record
    • 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top